Uniqure (NASDAQ:QURE) issued its earnings results on Thursday. The biotechnology company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.31), MarketWatch Earnings reports. Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 42.00%. The company had revenue of $1.54 million during the quarter, compared to analyst estimates of $17.87 million.
QURE traded up $2.34 during trading on Friday, hitting $41.73. 726,949 shares of the company’s stock were exchanged, compared to its average volume of 507,709. Uniqure has a fifty-two week low of $36.20 and a fifty-two week high of $76.69. The stock has a market cap of $1.85 billion, a P/E ratio of -13.29 and a beta of 1.24. The business’s 50 day moving average is $49.97 and its two-hundred day moving average is $55.53. The company has a quick ratio of 12.89, a current ratio of 12.89 and a debt-to-equity ratio of 0.12.
In related news, insider Robert Gut sold 26,875 shares of Uniqure stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total transaction of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 7,501 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $66.04, for a total value of $495,366.04. Following the sale, the chief executive officer now owns 307,332 shares of the company’s stock, valued at approximately $20,296,205.28. The disclosure for this sale can be found here. Insiders sold 40,002 shares of company stock worth $2,614,652 over the last ninety days. Insiders own 2.66% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Article: What is the accumulation/distribution indicator?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.